Australian Regulation of Autologous Human Cell and Tissue Products: Implications for Commercial Stem Cell Clinics
- 1 February 2020
- journal article
- editorial
- Published by Taylor & Francis in Regenerative Medicine
- Vol. 15 (2) , 1361-1369
Abstract
In 2018, Australia’s Therapeutic Goods Administration introduced regulatory reforms that set stricter criteria around the regulation of products derived from a patient’s own cells and tissues, posi...Keywords
Funding Information
- Australian Research Council Linkage Project (LP150100739)
This publication has 8 references indexed in Scilit:
- A roundtable on responsible innovation with autologous stem cells in Australia, Japan and SingaporeCytotherapy, 2018
- Concise Review: A Comprehensive Analysis of Reported Adverse Events in Patients Receiving Unproven Stem Cell-Based InterventionsStem Cells Translational Medicine, 2018
- Scientific considerations for the regulatory evaluation of cell therapy productsBiologicals, 2017
- Open for Business: A Comparative Study of Websites Selling Autologous Stem Cells in Australia and JapanRegenerative Medicine, 2017
- The deadly business of an unregulated global stem cell industryJournal of Medical Ethics, 2017
- Clarifying Stem-Cell Therapy’s Benefits and RisksNew England Journal of Medicine, 2017
- Global Distribution of Businesses Marketing Stem Cell-Based InterventionsCell Stem Cell, 2016
- Drug Advertising, Continuing Medical Education, and Physician Prescribing: A Historical Review and Reform ProposalJournal of Law, Medicine & Ethics, 2010